AVBP

Announcements

Nothing here yet

Daily updates

• ArriVent reported that the Phase 3 FURVENT study failed to meet its primary BICR-assessed PFS endpoint in first-line EGFR exon 20 insertion NSCLC.Oct 6, 2026

FDA designations

Nothing here yet

News

• ArriVent shares plunge after disappointing lung cancer trial dataOct 6, 2026
• ArriVent receives IND clearance for ARR-002 ADC targeting ovarian and endometrial cancersMay 7, 2026
• Arrivent presents final analysis of Firmonertinib monotherapy data from global Phase 1b study in EGFR PACC mutant non-small cell lung cancer at 2025 World Conference on Lung CancerSep 9, 2025
• ArriVent expects topline pivotal Phase 3 FURVENT data for firmonertinib in first-line NSCLC EGFR Exon20 insertions in early 2026Jul 21, 2025
• ArriVent reports positive interim data for Firmonertinib monotherapy in global Phase 1b study for EGFR PACC mutant non-small cell lung cancer and plans pivotal trialJun 23, 2025